New Opportunities and Threats in the Realm of Informed Consent

Abstract

Informed consent errors have fallen to sixth from first place as cited in most common clinical investigator findings by the U.S. Food and Drug Administration (FDA) over the past five years. While that suggests clinical researchers and sites have gotten better at handling this critically important